Brief: Aclaris Therapeutics Announces Positive Top-Line Results From Open-Label Phase 2A Trial Of Ati-2138, A Potent And Selective Investigational Inhibitor Of Itk And Jak3 Trial Achieves Primary And Key Secondary Endpoints

Aclaris Therapeutics

29/07/2025 22:19

Aclaris Therapeutics Inc ACRS.O:

ACLARIS THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM OPEN-LABEL PHASE 2A TRIAL OF ATI-2138, A POTENT AND SELECTIVE INVESTIGATIONAL INHIBITOR OF ITK AND JAK3; TRIAL ACHIEVES PRIMARY AND KEY SECONDARY ENDPOINTS

ACLARIS THERAPEUTICS INC - PRIMARY ENDPOINT CONFIRMS FAVORABLE TOLERABILITY PROFILE OF ATI-2138

ACLARIS THERAPEUTICS INC - ATI-2138 WELL TOLERATED WITH NO SEVERE ADVERSE EVENTS

Source text: ID:nGNX1cb42w

Further company coverage: ACRS.O